Keywords

• CAS 202189-78-4
• Bilastine
• 202189-78-4

Quick Details

• ProName: API Powder Bilastine CAS 202189-78-4
• CasNo: 202189-78-4
• Molecular Formula: C28H37N3O3
• Appearance: white crystal
• Application: UsesBilastine is a novel, nonsedating ...
• DeliveryTime: within 2-3 day
• PackAge: carton boc
• Port: tianjin/qingdao/shanghai
• ProductionCapacity: 1000000 Kilogram/Month
• Purity: 99%
• Storage: cool and dry
• Transportation: Air, sea or express
• LimitNum: 1 Kilogram
• Grade: Industrial Grade
• 1: 1

Superiority

Bilastine, a potent and selective histamine H1 receptor antagonist, was approved in Europe in 2010 for the treatment of allergic rhinoconjunctivitis (AR) and urticaria (hives or skin rash). The original synthesis of bilastine involves alkylation of 2-piperidinyl-1H-benzimidazole with a phenethyltosylate, the para position of which is substituted with a dimethyloxazoline moiety serving as a masked carboxylic acid group. Alkylation of the benzimidazole nitrogen with 2-chloroethyl ethyl ethers followed by unmasking of the oxazoline moiety with sulfuric acid provided bilastine.
In two major clinical trials, bilastine was effective at relieving allergic rhinitis as assessed by measuring the severity of nasal (obstruction, rhinorrhea, itching, sneezing) and nonnasal (ocular itching, tearing, ocular redness, itching of ears, and/or palate) symptoms.
UsesBilastine is a novel, nonsedating H1-antihistamine developed for symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria.
UsesLabelled Bilastine. It is a novel, nonsedating H1-antihistamine developed for symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria.

Details

Product  information

Product Name:Bilastine 
CAS:202189-78-4
MF:C28H37N3O3
MW:463.61
EINECS:
Mol File:202189-78-4.mol  
Melting point:202 °C
Boiling point:639.1±55.0 °C(Predicted)
Density 1.16±0.1 g/cm3(Predicted)
pka4.40±0.10(Predicted)

Description

Bilastine, a potent and selective histamine H1 receptor antagonist, was approved in Europe in 2010 for the treatment of allergic rhinoconjunctivitis (AR) and urticaria (hives or skin rash). The original synthesis of bilastine involves alkylation of 2-piperidinyl-1H-benzimidazole with a phenethyltosylate, the para position of which is substituted with a dimethyloxazoline moiety serving as a masked carboxylic acid group. Alkylation of the benzimidazole nitrogen with 2-chloroethyl ethyl ethers followed by unmasking of the oxazoline moiety with sulfuric acid provided bilastine.
In two major clinical trials, bilastine was effective at relieving allergic rhinitis as assessed by measuring the severity of nasal (obstruction, rhinorrhea, itching, sneezing) and nonnasal (ocular itching, tearing, ocular redness, itching of ears, and/or palate) symptoms.
UsesBilastine is a novel, nonsedating H1-antihistamine developed for symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria.
UsesLabelled Bilastine. It is a novel, nonsedating H1-antihistamine developed for symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria.

Company profile